Karyopharm Therapeutics
KPTI
106 hedge funds and large institutions have $563M invested in Karyopharm Therapeutics in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 21 closing their positions.
84% more capital invested
Capital invested by funds: $306M → $563M (+$256M)
60% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 25
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
3% more funds holding
Funds holding: 103 → 106 (+3)
0.69% more ownership
Funds ownership: 5.6% → 6.3% (+0.69%)
3% less call options, than puts
Call options by funds: $3.67M | Put options by funds: $3.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$54.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.4M |
| 4 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$11.5M |
| 5 |
Millennium Management
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.2M |
| 2 |
O
OrbiMed
New York
|
-$18.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.6M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.9M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.8M |
KPTI Hedge Fund Activity: Q3 2019 in Review
106 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2019, worth a combined $563M — up 84% from $306M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KPTI positions and 21 closed out — a net gain of 3 holders — while 40 added to existing stakes and 25 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $54.7M. The largest seller was Wellington Management Group, cutting an estimated $24.2M.
- 106 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2019, up from 103 in Q2 2019.
- Funds reported $563M of Karyopharm Therapeutics stock for Q3 2019, up 84% quarter-over-quarter.
- 24 funds opened new Karyopharm Therapeutics positions in Q3 2019 and 21 closed out, a net change of +3 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2019 was Avoro Capital Advisors, an estimated $54.7M added.
- The largest Karyopharm Therapeutics seller in Q3 2019 was Wellington Management Group, an estimated $24.2M sold.
Based on aggregated 13F filings for Q3 2019.